第一届全国哮喘防治大会暨中国哮喘联盟第一次工作会议征文通知

为了更进一步推动我国的哮喘防治工作，中华医学会呼吸病学分会哮喘学组和中国哮喘联盟拟于2006年8月11至14日在湖南省长沙市举办第一届全国哮喘防治大会暨中国哮喘联盟第一次工作会议（The 1st Congress of China Asthma Alliance．CCAA）。本次会议的宗旨是交流各地哮喘防治工作的经验，总结中国哮喘联盟成立一年来的工作情况，并对联盟未来的工作进行具体规划。     

中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会征文通知

为了进一步推动我国的哮喘防治工作,中华医学会呼吸病学分会哮喘学组和中国哮喘联盟定于2010年9月3-6日在江苏省扬州市举办中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会。本次会议的目的是交流各地哮喘防治和科研方面的经验和成果,总结中国哮喘联盟成立五年来的工作,并对全国哮喘防治先进省市和中国哮喘联盟控烟先锋和戒烟表率进行表彰。     

中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会征文通知

为了进一步推动我国的哮喘防治工作，中华医学会呼吸病学分会哮喘学组和中国哮喘联盟定于2010年9月3-6日在江苏省扬州市举办中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会。本次会议的目的是交流各地哮喘防治和科研方面的经验和成果，总结中国哮喘联盟成立五年来的工作，并对全国哮喘防治先进省市和中国哮喘联盟控烟先锋和戒烟表率进行表彰。     

中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会征文通知

为了进一步推动我国的哮喘防治工作,中华医学会呼吸病学分会哮喘学组和中国哮喘联盟定于2010年9月3-6日在江苏省扬州市举办中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会。本次会议的目的是交流各地哮喘防治和科研方面的经验和成果,总结中国哮喘联盟成立五年来的工作,并对全国哮喘防治先进省市和中国哮喘联盟控烟先锋和戒烟表率进行表彰。     

中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会征文通知

为了进一步推动我国的哮喘防治工作,中华医学会呼吸病学分会哮喘学组和中国哮喘联盟定于2010年9月3-6日在江苏省扬州市举办中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会。本次会议的目的是交流各地哮喘防治和科研方面的经验和成果,总结中国哮喘联盟成立五年来的工作,并对全国哮喘防治先进省市和中国哮喘联盟控烟先锋和戒烟表率进行表彰。     

中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会征文通知

为了进一步推动我国的哮喘防治工作,中华医学会呼吸病学分会哮喘学组和中国哮喘联盟定于2010年9月3-6日在江苏省扬州市举办中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会。本次会议的目的是交流各地哮喘防治和科研方面的经验和成果,总结中国哮喘联盟成立五年来的工作,并对全国哮喘防治先进省市和中国哮喘联盟控烟先锋和戒烟表率进行表彰。     

中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会征文通知

为了进一步推动我国的哮喘防治工作,中华医学会呼吸病学分会哮喘学组和中国哮喘联盟定于2010年9月3-6日在江苏省扬州市举办中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会。本次会议的目的是交流各地哮喘防治和科研方面的经验和成果,总结中国哮喘联盟成立五年来的工作,并对全国哮喘防治先进省市和中国哮喘联盟控烟先锋和戒烟表率进行表彰。     

中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会征文通知

为了进一步推动我国的哮喘防治工作，中华医学会呼吸病学分会哮喘学组和中国哮喘联盟定于2010年9月3-6日在江苏省扬州市举办中华医学会第七届全国哮喘学术会议暨中国哮喘联盟第三次大会。本次会议的目的是交流各地哮喘防治和科研方面的经验和成果，总结中国哮喘联盟成立五年来的工作，     

评估哮喘控制情况的方法

哮喘研究历史近百年但其病因和发病机制都尚未完全清楚,可哮喘危害很多,治疗方法亦不断在改进。自1993年美国国立卫生院心肺血液研究所（NHLBI）联合世界卫生组织（WHO）成立了＂全球哮喘防治创议＂专家组,并于1995年出版了一套名为《全球哮喘防治的创议》（Global Initiative forAsthma,GINA）系列丛书。哮喘的治疗越来越规范,但是全球     

内科医生哮喘防治知识调查

近年来，对支气管哮喘（哮喘）的规范化管理和防治受到了普遍的关注。哮喘管理和防治的全球策略［’］已在许多国家得到推广应用并取得了一定效果。为了解临床医生对哮喘防治知识的掌握和应用，我们对上海市区94位内科医生进行了问卷调查。现将结果报告如下。对象与方法．一、调查对象：上海市区内科医生94名。其中主任或副主任医师33名，主治医师31名，住院医帅30名。二、调查方法和内容：采用问卷形式。调查内容包括三部分。（一）有关哮喘诊断及病情严重性的评判指标1．哮喘的诊断：（l）病史和症状；（2）听到哮鸣音；（3）血嗜酸性细胞…     

Strategies for the management of asthma

Abstract The aims of treating patients with asthma are to relieve symptoms, to prevent symptoms and exacerbations, and to prevent long-term deterioration in lung function. It is the role of medical practitioners to inform the patient what asthma is, and to develop a plan to achieve the aims for the individual, recognizing that asthma is frequently a chronic, lifelong disease. Most patients can be diagnosed, assessed for severity and causes, and treated in primary care practices, however sometimes help from an asthma clinic or a specialist is required. The most important management decision is to determine whether the patient needs inhaled corticosteroids; subsequently, decisions about dose, duration and method of delivery of treatment can be tailored to the individual depending on the preferences and social conditions of the patient. The aim of this article is to present the latest strategies for the management of asthma and the simplest methods for their implementation. Important new strategies include careful assessment of the severity; the immediate introduction of a plan that is tailored for the individual and aimed at the possible reversing of the disease; detailed instructions for management of exacerbations and the combined use of inhaled corticosteroids with a long-acting bronchodilator. It is becoming clear that these strategies obviate dependence on oral corticosteroids in newly diagnosed asthmatic patients. Furthermore, relatively low doses of inhaled corticosteroids can be used to maintain good control if used in conjunction with other therapies. The role of newly developed antagonists to leukotrienes is not yet known but it may well be useful in mild asthma and in special forms of the disease, such as those sensitive to aspirin. In the future, the most important strategy will be to prevent the disease.     

Anti-IgE antibodies for the treatment of asthma

PURPOSE OF REVIEW: Allergic asthma is a hypersensitivity reaction initiated by immunologic mechanisms mediated by IgE antibodies. IgE plays a central role in the initiation and propagation of the inflammatory cascade and thus the allergic response. Targeting factors involved in the allergic response, such as IgE, is a novel strategy for new therapies. Attenuating allergic disease by specifically inhibiting IgE and the development of the monoclonal anti-IgE antibody, omalizumab, were major breakthroughs in asthma management. RECENT FINDINGS: Several studies have shown that omalizumab has significant anti-inflammatory effects and that it may act on multiple components of the inflammatory cascade. Specific binding of IgE by omalizumab reduces both the early allergic response and the late allergic response and symptoms of IgE-mediated allergy. The long-term clinical efficacy of omalizumab has been demonstrated along with improvements in quality of life. As add-on therapy in severe asthma, omalizumab reduces the requirement for inhaled corticosteroids and improves disease control. Clinical studies have shown that the patients who benefit most from omalizumab therapy are those at high risk of exacerbations, those with poorly controlled and/or severe asthma, and those with IgE-mediated comorbidities. SUMMARY: Omalizumab is a significant addition to current asthma treatments and shows great promise as a therapy for allergic asthma and for patients with concomitant allergic rhinitis. This is particularly true for difficult-to-treat patients with moderate to severe allergic asthma who have poorly controlled disease on conventional therapies, experience severe adverse effects secondary to high-dose or prolonged corticosteroid treatment, have frequent exacerbations, and/or are at high risk of hospitalization. Future studies will continue to investigate the anti-inflammatory mechanisms of anti-IgE therapy. Because many of these mechanisms are common to all IgE-mediated allergic diseases, the efficacy of omalizumab in other allergic diseases should be further explored.     

Guidelines for the management of work-related asthma

Work-related asthma, which includes occupational asthma and work-aggravated asthma, has become one of the most prevalent occupational lung diseases. These guidelines aim to upgrade occupational health standards, contribute importantly to transnational legal harmonisation and reduce the high socio-economic burden caused by this disorder. A systematic literature search related to five key questions was performed: diagnostics; risk factors; outcome of management options; medical screening and surveillance; controlling exposure for primary prevention. Each of the 1,329 retrieved papers was reviewed by two experts, followed by Scottish Intercollegiate Guidelines Network grading, and formulation of statements graded according to the Royal College of General Practitioners' three-star system. Recommendations were made on the basis of the evidence-based statements, which comprise the following major evidence-based strategic points. 1) A comprehensive diagnostic approach considering the individual specific aspects is recommended. 2) Early recognition and diagnosis is necessary for timely and appropriate preventative measures. 3) A stratified medical screening strategy and surveillance programme should be applied to at-risk workers. 4) Whenever possible, removing exposure to the causative agent should be achieved, as it leads to the best health outcome. If this is not possible, reduction is the second best option, whereas respirators are of limited value. 5) Exposure elimination should be the preferred primary prevention approach.     

Bronchial thermoplasty for the treatment of asthma

Asthma is an increasingly prevalent disease, particularly in industrialized countries. With modern treatment, many patients can expect good asthma control; however, a significant minority continue to have excessive symptoms. Bronchial thermoplasty is a novel approach to treating asthma in which the hypertrophied airway smooth muscle present in the asthmatic airway is specifically targeted and depleted using thermal energy. In this article, we review the early animal and human development of the technique, summarize the randomized trials carried out in patients to date, discuss proposed mechanisms of action, and suggest directions for future work.